Phase 4 N=60 Low Dose Amisulpride Vs Olanzapine-Fluoxetine Combination in Post-Schizophrenic Depression
Post-Schizophrenic Depression
Primary: Calgary Depression Scale for Schizophrenia (CDSS) — 8.31; 8.62 score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=126 Sustaining Remission of Psychotic Depression
Psychotic Depression
Primary: Number of Subjects at Risk of Relapse During the Randomized Phase. — 13; 34 Participants
Phase 3 N=259 Study of Pharmacotherapy of Psychotic Depression
Major Depressive Disorder With Psychotic Features
Primary: Remission of Depression Hamilton Depression Scale (Ham-D) and Psychosis Schedule for Affective Disorders in Schizophrenia - Delusional Item (SADS) During the Course of…
Phase 2 N=8 Poststroke Depression in Hemorrhagic Stroke
Stroke Hemorrhagic · Depression
Primary: Depression — 12.33; 6 units on a scale
Phase 2 N=12 Pramipexole to Target "Anhedonic Depression"
Depression, Bipolar · Depression, Unipolar · Dysthymia
Primary: Dimensional Anhedonia Rating Scale (DARS) Score — 15.75; 33.08 score on a scale
N/A N=66 Implementing Evidence in the Detection and Treatment of Post Stroke Depression
Mental Health · Neurology · Health Services
Primary: PHQ-9 — 6.4; 4.4 units on a scale
Phase 4 N=188 Treatment for Post-Stroke Depression
Stroke · Depression
Primary: Twelve Week Depression Outcomes — 10.6 HAM-D depression score
Phase 4 N=95 DECIFER: Depression and Citalopram In First Episode Recovery
Schizophrenia · Schizophreniform Disorder
Primary: Calgary Depression Scale for Schizophrenia (CDSS) — 1.93; 2.26; 1.83; 2.58 units on a scale
Phase 2 N=52 Treatment of Post-Traumatic Brain Injury (TBI) Depression
Depression
Primary: Depression at Baseline — 27.5; 25.2 units on a scale
Phase 3 N=386 To Determine Long Term Efficacy and Safety of Asenapine in Schizophrenic Patient Population (A7501012)(COMPLETED)(P05770)
Schizophrenia
Primary: Time to Relapse or an Impending Relapse — 0; 3; 1; 14 relapses
Phase 4 N=62 Antidepressant Controlled Trial for Negative Symptoms in Schizophrenia
Schizophrenia
Primary: PANSS Negative Symptom Score — 21.5; 23 units on a scale — p=0.36
Phase 2 N=92 Efficacy, Safety, and Tolerability of SPD489 in Adults With Schizophrenia and Predominant Negative Symptoms
Schizophrenia and Predominant Negative Symptoms
Primary: Change From Open-label Baseline in Modified Scale for the Assessment of Negative Symptoms (SANS-18) Total Score at Week 10 Open-label Phase, Last Observation Carried…
Phase 3 N=187 Long-Term Efficacy and Safety of Asenapine Using Haloperidol as a Positive Control (41513)(COMPLETED)(P05785)
Schizophrenia
Primary: Loss of Effect Over Time — 7; 15; 6; 3 Participants
N/A N=404 An Integrated Program for the Treatment of First Episode of Psychosis
Schizophrenia · Schizoaffective Disorder · Schizophreniform Disorder
Primary: Mean Heinrichs-Carpenter Quality of Life Scale Scores Over Time — 51.25; 55.13; 59.15; 60.08 score on a scale — p=0.0145
N/A N=88 Cognitive-Behavioral Therapy in Veterans With Schizophrenia
Schizophrenia · Schizoaffective Disorder
Primary: Changes in Positive Schizophrenia Symptoms — 3.21; 3.30; 3.04; 2.89 units on a scale — p=.30
Phase 3 N=72 Ziprasidone vs. Sertraline/Haloperidol in Psychotic Depression
Affective Disorders
Primary: 21 Item Hamilton Depression Rating Scale — 13.6; 11.0 Units on Hamilton Depression Scale
Phase 4 N=60 Does The Addition Of Divalproex Sodium ER To An Atypical Antipsychotic Drug (APD) Improve Cognition And Psychopathology In Outpatients With Schizophrenia (SCH) Or Schizoaffective Disorder (SAD)?
Schizophrenia · Schizoaffective Disorder
Primary: Change in Cognition and Psychopathology Disorders as Measured on the MATRICS Consensus Cognitive Battery (MCCB) — 14.1; 14.3 units on a scale
Phase 4 N=46 Antidepressant Plus Asenapine Versus Antidepressant Plus Placebo for Depression
Major Depressive Disorder Without Psychotic Features
Primary: Change in MADRS Total Score — -14.29; -11.61 units on a scale
Phase 4 N=59 Desvenlafaxine vs. Placebo Treatment of Chronic Depression
Dysthymic Disorder · Dysthymia · Chronic Depressive Disorder
Primary: Hamilton Rating Scale for Depression (HDRS24) — 14.63; 14.21 units on a scale — p=0.09
N/A N=3 SCED - Wisdom Enhancement for Post-Stroke Depression
Post-stroke Depression
Primary: Visual Analogue Scale (VAS) - Mood — 3.53; 5.23 Scores on a scale
N/A N=60 Impact of Intensive Social Interaction on Post-Stroke Depression in Individuals With Aphasia
Post-stroke Depression · Post-stroke Aphasia
Primary: Change in Beck's Depression Inventory, BDI. — -12.6; -5.8 score on a scale
N/A N=153 Social Cognition Intervention
Psychosis
Primary: Mayer-Salovey-Caruso Emotional Intelligence Test (MSCEIT) — 87.30; 87.30; 88.46; 89.23 units on a scale — p=< .05
N/A N=20 Clinical Trial of Dipyridamole in Schizophrenia
Schizophrenia · Schizoaffective Disorder · Schizophreniform Disorder
Primary: Change in Positive Symptoms by Treatment Assignment — 2.222; 1.400; 1.60; 1.00 units on a scale
Phase 2 N=143 SPD489 in Adults With Persistent Executive Function Impairments (EFI) and Partial or Full Remission of Recurrent Major Depressive Disorder
Major Depressive Disorder
Primary: Change From Baseline in Behavior Rating Inventory of Executive Function - Adult Version Global Executive Composite T-score (BRIEF-A GEC T) at Week 9, Last Observation…
N/A N=23 Exercise and Brain Stimulation for Post-stroke Depression
Stroke
Primary: Change From Baseline to Post Training in Hamilton Rating Scale for Depression — -2.75; -7.5; -7.83; -2.29 units on a scale
Phase 4 N=60 Psychosocial Therapy and Risperidone Treatment in Work Performance in Recent-Onset Schizophrenia
Schizophrenia
Primary: Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery (MCCB) — 6.7; 0.9; 3.9; 5.9 T scores — p=<0.03
Phase 4 N=296 Pramipexole Versus Placebo in Parkinson's Disease (PD) Patients With Depressive Symptoms
Parkinson Disease · Depression
Primary: Change From Baseline in the Beck Depression Inventory-Version 1A (BDI-IA) Total Score at Week 12 — -4; -5.9 Score on scale — p=0.0103
Phase 2 N=39 Lexapro and Pramipexole and to Treat Major Depression
Major Depression
Primary: Montgomery Asberg Depression Rating Scale (MADRS) — 22.629; 26.102; 29.455 Score on a scale — p=.018
Phase 4 N=21 Brexpiprazole for Bipolar Depression
Bipolar Depression
Primary: The Montgomery-Asberg Depression Rating Scale (MADRS) — 31.95; 9.95; 10.95 score on a scale — p=<.001
N/A N=63 Treatment of Schizophrenia With L-tetrahydropalmatine (l-THP): a Novel Dopamine Antagonist With Anti-inflammatory and Antiprotozoal Activity
Schizophrenia
Primary: Positive and Negative Symptom Improvement — 41.3; 40.3; 36.6; 37.3 score on a scale